ATE479441T1 - Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien - Google Patents

Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien

Info

Publication number
ATE479441T1
ATE479441T1 AT00964937T AT00964937T ATE479441T1 AT E479441 T1 ATE479441 T1 AT E479441T1 AT 00964937 T AT00964937 T AT 00964937T AT 00964937 T AT00964937 T AT 00964937T AT E479441 T1 ATE479441 T1 AT E479441T1
Authority
AT
Austria
Prior art keywords
cadherin
treating inflammatory
compositions
methods
inflammatory diseases
Prior art date
Application number
AT00964937T
Other languages
English (en)
Inventor
Michael Brenner
Xavier Valencia
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE479441T1 publication Critical patent/ATE479441T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT00964937T 1999-09-03 2000-09-01 Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien ATE479441T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15245699P 1999-09-03 1999-09-03
US15349099P 1999-09-13 1999-09-13
PCT/US2000/024101 WO2001017557A1 (en) 1999-09-03 2000-09-01 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents

Publications (1)

Publication Number Publication Date
ATE479441T1 true ATE479441T1 (de) 2010-09-15

Family

ID=26849576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964937T ATE479441T1 (de) 1999-09-03 2000-09-01 Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien

Country Status (9)

Country Link
EP (2) EP1207905B1 (de)
AT (1) ATE479441T1 (de)
AU (1) AU7574700A (de)
CA (1) CA2384115C (de)
DE (1) DE60044904D1 (de)
DK (1) DK1207905T3 (de)
ES (1) ES2592507T3 (de)
PT (1) PT1207905E (de)
WO (1) WO2001017557A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE483976T1 (de) * 2001-06-05 2010-10-15 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
WO2009089062A2 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
JP5886283B2 (ja) 2010-07-15 2016-03-16 アドヘロン セラピューティクス，インコーポレイテッド カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3652761A (en) 1969-09-04 1972-03-28 Corning Glass Works Immunochemical composites and antigen or antibody purification therewith
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4478946A (en) 1981-07-02 1984-10-23 South African Inventions Development Corporation Carrier bound immunosorbent
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4554088A (en) 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5597725A (en) 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
JPH07500019A (ja) 1992-04-17 1995-01-05 ドーニー　アイ　インスティテュート カドヘリン物質および方法
US5565325A (en) 1992-10-30 1996-10-15 Bristol-Myers Squibb Company Iterative methods for screening peptide libraries
EP0688223A4 (de) 1993-03-12 1998-05-13 Cellcor Inc -i(IN VITRO) 'ASSAY' ZUM MESSEN DES GRADES DER AKTIVIERUNG VON IMMUNZELLEN
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
EP0740791A4 (de) 1994-01-05 2000-04-05 Arqule Inc Systematische modulare herstellung von aminimid- und oxazolonbasierten molekülen mit ausgewählten eigenschaften
US6037134A (en) 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
EP0804249A2 (de) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5908609A (en) 1996-06-10 1999-06-01 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
CA2203718A1 (en) * 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
CA2225187A1 (en) 1997-07-14 1999-01-14 Universite D'ottawa/ University Of Ottawa Xaf genes and polypeptides: methods and reagents for modulating apoptosis
US6248864B1 (en) * 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
CA2349835A1 (en) * 1998-10-30 2000-05-11 The University Of British Columbia Cadherin-11 expression, an assay and treatment for cellular invasiveness

Also Published As

Publication number Publication date
ES2592507T3 (es) 2016-11-30
EP2267029B1 (de) 2016-06-15
EP2267029A3 (de) 2011-06-22
EP1207905A1 (de) 2002-05-29
DK1207905T3 (da) 2011-01-03
DE60044904D1 (de) 2010-10-14
PT1207905E (pt) 2010-12-07
WO2001017557A1 (en) 2001-03-15
WO2001017557A9 (en) 2002-09-12
CA2384115A1 (en) 2001-03-15
EP1207905B1 (de) 2010-09-01
AU7574700A (en) 2001-04-10
EP2267029A2 (de) 2010-12-29
CA2384115C (en) 2016-08-02

Similar Documents

Publication Publication Date Title
DE69821132D1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE515268T1 (de) Verwendung von op-1 zur behandlung von knorpeldefekten
BR9705727A (pt) Heterocicilos com anel de cinco membros como inibidores da adesão de leucócitos e como antigonistas de vla-4.
ATE238307T1 (de) Substituierte porphyrinen
ATE282591T1 (de) Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
EA200001176A1 (ru) Гетероциклические ингибиторы p38
DE69922228D1 (de) Verfahren zur reduzierung der mineralisierung von gewebe zum gebrauch bei transplantation
ATE481487T1 (de) Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
DE69528475T2 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DE69931946D1 (de) Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen
DE58903736D1 (de) Verfahren zur behandlung von biomassen, z.b. klaerschlaemmen, guelle, usw.
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
WO2003018752A3 (en) An organotypic intestinal culture and methods of use thereof
ATE311206T1 (de) Substituierte porphyrine
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE60042630D1 (de) Verfahren zur Herstellung von laminierten Ringen und Salzschmelzenzusammensetzung zur Verwendung bei diesem Verfahren
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
MX9101861A (es) Novedosos 2-sacarinilmetil ari carboxilatos utiles como inhibidores de enzima proteolitica y composiciones y metodo para usarlos
ATE551054T1 (de) Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus
ATE235466T1 (de) Heterozyklen zur behandlung von gutartiger prostata-hyperplasie und deren zwischenprodukte

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1207905

Country of ref document: EP